

Marie-Rose Spirlet,^{a*} Amaury Graulich^b and Jean-Francois Liégeois^b

^aDépartement de Physique, B5, Université de Liège, Sart Tilman, B-4000 Liège, Belgium, and

^bNatural and Synthetic Drugs Research Centre, Laboratory of Medicinal Chemistry, 1 avenue de l'Hôpital (B36), B-4000 Liège, Belgium

Correspondence e-mail: mrspsirlet@ulg.ac.be

Key indicators

Single-crystal X-ray study

$T = 293\text{ K}$

Mean $\sigma(\text{C}-\text{C}) = 0.004\text{ \AA}$

R factor = 0.050

wR factor = 0.106

Data-to-parameter ratio = 13.8


For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

8-Methyl-6-(4-methylpiperazin-1-yl)-11H-pyrido[2,3-b][1,4]benzodiazepine

The conformation of the title compound, $\text{C}_{18}\text{H}_{21}\text{N}_5$, is very similar to that observed in other diaryldiazepine structures such as clozapine and clozapine dihydrobromide. $\text{N}-\text{H}\cdots\text{H}$ hydrogen-bond interactions result in the formation of a dimer.

Comment

The title compound binds to the dopamine D_4 receptor with affinity up to 25 times superior to that for the dopamine D_2 receptor and shows reduced affinities for other receptors (Liégeois *et al.*, 1995). As for clozapine in Parkinsonian patients, the title compound was shown to reduce L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias at low doses in Parkinsonian monkeys (Hadj Tahar *et al.*, 2000). The molecular conformation observed for the title compound (Fig. 1) is in agreement with the conformation described for two similar compounds, *viz.* $\text{C}_{18}\text{H}_{19}\text{ClN}_4$ (clozapine; Petcher & Weber, 1976) and $\text{C}_{18}\text{H}_{21}\text{ClN}_4\text{Br}_2$ (clozapine dihydrobromide; Fillers & Hawkinson, 1982). The diazepine moiety (central seven-membered heterocycle) is in a boat conformation. The dihedral angle between the planes of the aromatic rings is $122.21(9)^\circ$. The piperazine side chain adopts a classical chair conformation. The distances between the basic N atom of the piperazine and the centres of each of the aromatic rings are 6.085 and 7.720 Å, respectively. Intermolecular contacts (Table 1) indicate $\text{N}-\text{H}\cdots\text{N}$ hydrogen bonding, with the formation of dimers, as shown in Fig. 2.



Experimental

The title compound was prepared according to methods described previously (Liégeois *et al.*, 1993). Briefly, a nitrobenzamide was first prepared by the reaction of 2-nitrobenzoyl chloride with 3-amino-2-chloropyridine. The nitro moiety was reduced using an acidic stannous chloride mixture to give an anthranilamide derivative. The diazepinone ring was then obtained by nucleophilic substitution of the Cl atom by heating in diethyleneglycol monomethylether. The lactam derivative was finally reacted with an excess of *N*-methylpiperazine and titanium tetrachloride in refluxing toluene to give the

Received 1 October 2003

Accepted 17 November 2003

Online 22 November 2003




Figure 1

The title compound, with the atom-labelling scheme. Displacement ellipsoid are shown at the 50% probability level.

title compound. Single crystals suitable for X-ray analysis were grown from a solution in toluene.

Crystal data

$C_{18}H_{21}N_5$	Mo $K\alpha$ radiation
$M_r = 307.40$	Cell parameters from 21 reflections
Orthorhombic, $Pbca$	$\theta = 15.2\text{--}17.5^\circ$
$a = 13.0331(19) \text{ \AA}$	$\mu = 0.08 \text{ mm}^{-1}$
$b = 15.610(3) \text{ \AA}$	$T = 293(2) \text{ K}$
$c = 16.514(3) \text{ \AA}$	Prism, yellow
$V = 3359.7(10) \text{ \AA}^3$	$0.35 \times 0.30 \times 0.25 \text{ mm}$
$Z = 8$	
$D_x = 1.215 \text{ Mg m}^{-3}$	

Data collection

Bruker P4 diffractometer	$R_{\text{int}} = 0.031$
$2\theta/\omega$ scans	$\theta_{\text{max}} = 25.0^\circ$
Absorption correction: ψ scan (North <i>et al.</i> , 1968)	$h = -1 \rightarrow 15$
$T_{\text{min}} = 0.915$, $T_{\text{max}} = 0.964$	$k = -1 \rightarrow 18$
6621 measured reflections	$l = -1 \rightarrow 19$
2952 independent reflections	3 standard reflections
1441 reflections with $I > 2\sigma(I)$	every 97 reflections
	intensity decay: none

Refinement

Refinement on F^2	H atoms treated by a mixture of independent and constrained refinement
$R[F^2 > 2\sigma(F^2)] = 0.050$	$w = 1/[\sigma^2(F_o^2) + (0.034P)^2]$
$wR(F^2) = 0.106$	where $P = (F_o^2 + 2F_c^2)/3$
$S = 0.92$	$(\Delta/\sigma)_{\text{max}} < 0.001$
2952 reflections	$\Delta\rho_{\text{max}} = 0.15 \text{ e \AA}^{-3}$
214 parameters	$\Delta\rho_{\text{min}} = -0.15 \text{ e \AA}^{-3}$

Table 1

Hydrogen-bonding geometry ($\text{\AA}$, $^\circ$).

$D\text{--}H\cdots A$	$D\text{--}H$	$H\cdots A$	$D\cdots A$	$D\text{--}H\cdots A$
$N5\text{--}H5\cdots N7^i$	0.917 (16)	2.300 (17)	3.214 (3)	175 (2)

Symmetry code: (i) $1 - x, -y, 1 - z$.

All H atoms were located from difference Fourier maps. H atoms attached to C atoms were treated as riding [$C\text{--}H = 0.93\text{--}0.97 \text{ \AA}$ and $U_{\text{iso}}(H) = 1.5U_{\text{eq}}(C)$ (methyl groups) or $1.2U_{\text{eq}}(C)$ (other H atoms)],




Figure 2

The $N\text{--}H\cdots N$ interactions, leading to the formation of dimers. [Symmetry code: (i) $-x + 1, -y, -z + 1$.]

and the coordinates and $U_{\text{iso}}(H)$ value of that belonging to the NH group were refined with a restraint of $N\text{--}H = 0.917(16) \text{ \AA}$.

Data collection: *XSCANS* (Siemens, 1996); cell refinement: *XSCANS*; data reduction: *SHELXTL* (Siemens, 1991); program(s) used to solve structure: *SHELXTL*; program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP-3* (Farrugia, 1997); software used to prepare material for publication: *SHELXTL*.

The authors are grateful to the Inter-university Institute for Nuclear Sciences and to the National Fund for Scientific Research (Brussels) for financial support. JFL is a senior research associate of the Fonds National pour la Recherche Scientifique (FNRS) of Belgium. AG is a research fellow of the Fonds pour la Formation à la Recherche dans l'Industrie et l'Agriculture (FRIA).

References

- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Fillers, J. P. & Hawkinson, S. W. (1982). *Acta Cryst.* **B38**, 1750–1753.
- Hadj Tahar, A., Bélanger, N., Bangassoro, E., Grégoire, L. & Bédard, P. J. (2000). *Eur. J. Pharmacol.* **399**, 183–186.
- Liégeois, J.-F., Bruhwyler, J., Damas, J., Nguyen, T. P., Chleide, E., Mercier, M., Rogister, F. & Delarge, J. (1993). *J. Med. Chem.* **36**, 2107–2114.
- Liégeois, J.-F., Bruhwyler, J., Damas, J., Rogister, F., Masereel, B., Géczy, J. & Delarge, J. (1995). *Eur. J. Pharmacol.* **273**, R1–3.
- North, A. C. T., Philips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
- Petcher, T. J. & Weber, H.-P. (1976). *J. Chem. Soc. Perkin Trans. 2*, pp. 1415–1420.
- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Siemens (1991). *SHELXTL*. Release 4.1. Siemens Analytical X-ray Instruments, D-76181 Karlsruhe, Germany.
- Siemens (1996). *XSCANS*. Version 2.2. Siemens Analytical X-ray Instruments, D-76181 Karlsruhe, Germany.